Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-Dose Safety and PK/PD Study of Globalagliatin (SY-004) in Healthy Chinese Subjects
NCT03171623Phase 1Completed
- Sponsor
- Yabao Pharmaceutical Group Co., Ltd.
- Start
- Apr 2017
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of globalagliatin in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Yabao Pharmaceutical Group Co., Ltd. Primary endpoint: Safety and tolerability of single dose of SY-004. Started Apr 2017; status: completed.
02
Drugs
globalagliatin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03171623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03171623.